<div>
  <ul>
    <li>
      <p>
        Formation Bio has partnered with Sanofi and OpenAI to create AI-powered software aimed at expediting drug development. The financial details of the partnership were not disclosed.
      </p>
    </li>
    <li>
      <p>
        The partnership will integrate proprietary data, AI, and industry expertise to design AI models specifically crafted for the pharma industry. The aim is to streamline all stages of the drug development lifecycle to accelerate the delivery of novel therapeutics.&nbsp;
      </p>
    </li>
    <li>
      <p>
        Formation Bio, formerly TrialSpark, focuses on accelerating drug development through a proprietary platform based on modern data, LLMs, AI agents, and other technology. The company acquires clinical-stage drugs from pharmaceutical companies, universities, and biotech firms and leverages its AI platform to develop these assets into commercialization. 
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.morningstar.com/news/globe-newswire/1000951857/press-release-sanofi-formation-bio-and-openai-announce-first-in-class-ai-collaboration">
      Press release
    </a>
  </p>
  <p>
    <a href="https://www.pharmaceutical-technology.com/news/sanofi-partnership-drug-development/">
      Pharmaceutical Technology
    </a>
  </p>
</div>


AI Drug Discovery

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 <p>Formation Bio has initiated a collaboration with Sanofi and OpenAI with an objective to develop AI-powered software that would quicken drug development. The specific financial details of this collaboration were not disclosed.</p>
 <p>This partnership aims to amalgamate proprietary data, AI, and industry expertise to devise AI models tailored specifically for the pharmaceutical industry. The primary goal is to enhance efficiency across every stage of the drug development process, thereby expediting the delivery of innovative therapeutics.</p>
 <p>Previously known as TrialSpark, Formation Bio specializes in fast-tracking drug development using a proprietary platform that includes modern data, LLMs, AI agents, and other technology. The company sources clinical-stage drugs from various entities like pharmaceutical companies, universities, and biotech firms and then uses its AI platform to develop these assets until they reach commercialization.</p>

</div>

Formation Bio, Sanofi, and OpenAI partner to accelerate drug development through AI

Retail investors demanding sophisticated passive investment strategies are looking for an edge.

Retail Trading Infrastructure

<div>
 
 <p>Online trading platform Robinhood has introduced joint investment accounts. This feature lets users manage investments collaboratively and simplifies the investment process by consolidating financial assets into one account.</p>
 <p>The user-friendly joint investment account merges individual accounts, enables shared access, eases fund transfers, and provides easy switching between individual and joint accounts.</p>
 <p>With no extra charges, Robinhood aims to offer users additional financial growth opportunities by including benefits like a 1% deposit boost and a 5% APY on non-invested cash in the joint investment accounts.</p>
 
</div>

Robinhood launches joint investment accounts

<div>
 <p>Online trading platform eToro, based in Israel, has formed a partnership with the London Stock Exchange. This collaboration aims at offering users access to over 1,000 additional UK stocks and improving the quality of market data.</p>
 <p>This partnership will phase in the inclusion of more UK stocks to eToro's platform over the forthcoming months, growing from their existing offering of over 400 listed UK companies. eToro aims to enhance the trading experience for its global clientele, comprising of 3.8 million registered UK users. This enhancement will involve offering access to smaller stocks and better quality pricing data.</p>
 <p>This joint endeavor is a part of the strategies of eToro to tailor their offerings for the UK market. The strategy is in line with the prior launch of its ISA product and the provision for UK users to directly invest from GBP-denominated eToro Money accounts.</p>
</div>

eToro partners with London Stock Exchange to expand UK stock offerings

Generating, collecting, and analyzing enterprise data will never be the same.

Edge Computing

<div>
 
 <p>StorMagic, a provider of edge computing, has received an investment from Palatine Growth Credit Fund. The amount was not disclosed.</p>
 <p>The investment will be used to support the company's growth.</p> 
 <p>Established in 2006, StorMagic offers edge computing solutions, which includes software-defined storage and hyper-converged infrastructure specifically designed for edge environments, enabling businesses to efficiently manage data across diverse locations.</p>
 
</div>

StorMagic secures funding from Palatine Growth Credit Fund

Platforms to make the most of cloud infrastructure

Cloud Optimization Tools

<div>
 
 <p>In a Series B funding round led by Highsage Ventures, cloud cost management platform Archera raised USD 17 million. Other participants included Ridge Ventures, Amplify Partners, and PSL Ventures.</p>
 <p>The company plans to use this funding to provide more cloud financing and commitment insurance products, support Azure and Google Cloud platforms, expand their team, and enhance financial reporting services for enterprise clients.</p>
 <p>Established in 2019, Archera's platform aids businesses in minimizing cloud expenses and enhancing efficiency by analyzing usage patterns, predicting future costs, and suggesting suitable purchasing strategies for cloud resources. The company boasts of around 400 clients and generates USD 7 million in revenue annually.</p>

</div>

Archera raises USD 17 million in Series B funding for product development and recruitment

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

<div>

 <p>Alto Neuroscience, a biopharmaceutical company, has been awarded a grant of USD 11.7 million by the Wellcome Trust. This funding is intended to aid the Phase IIb clinical trials of their drug candidate, ALTO-100, which is under investigation as a potential treatment for bipolar depression. The trial is projected to enrol around 200 participants and anticipates revealing primary data by 2026.</p>
 <p>The company specializes in precision psychiatry, using neurobiology to create individualized treatments for various mental health conditions. Through the Precision Psychiatry Platform, Alto Neuroscience utilizes brain biomarkers, such as EEG activity, neurocognitive evaluations, and information collected from wearables, to determine the likely success rate of specific drug candidates among different patients. Its drug development pipeline includes a range of clinical-stage assets, including ALTO-100 and ALTO-300 for major depressive disorder, ALTO-101 targeted at cognitive impairments related to schizophrenia, and ALTO-203 for treating major depressive disorder with anhedonia.</p>

</div>

Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100

<div>
 
 <p>Quest Diagnostics and Becton, Dickinson, and Company (BD) have formed a strategic partnership aimed at developing companion diagnostics (CDx) for enhanced treatment options for cancer and other diseases. BD is an internationally recognized medical technology company that specializes in the development, manufacture, and sale of medical devices, instrument systems, and reagents.</p>
 <p>With a focus on providing a comprehensive solution for the development of CDx, the partnership will be involved in manufacturing and distributing diagnostic kits approved by the FDA. They intend to use flow cytometry technology in the process, which could assist in selecting treatments for patients with cancer. This could potentially improve clinical outcomes and help to reduce healthcare costs.</p>
 
</div>

Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases

Technology providers that enhance satellite operations

Next-gen Satellites

<div>
 <p>Commercial aerospace company, USPACE Technology Group Limited (USPACE), has announced the launch of six commercial optical satellites. They will also be offering different satellite components and services. </p>
 <p>In addition, USPACE revealed their new Hong Kong Satellite Manufacturing Center, along with the details of their optical satellites on their <a href="https://www.uspace.com/categories.html"> website </a>. These satellites vary in range from 0.5 m to 5 m, with prices varying from USD 35,000 to USD 990,000. Future releases will include separation seats, multi-satellite dispensers, and 0.5-meter resolution lightweight cameras.</p>
</div>

USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products

<div>
 <p>Sweden is carrying out the "Stella" study which aims to investigate the possibility of launching a small satellite from a Saab Gripen fighter jet. This is to enhance its operations. The initiative, led by the Swedish Air Force and Defense Research Agency, takes inspiration from Italy's recent plan to launch small satellites via the Eurofighter Typhoon.</p>
 <p>The Swedish Air Force has been notably investing in long-range air-to-ground missile systems for the nation's Gripen C/D fleet. However, no specific details about the budget or financial aspects of this new potential satellite launch strategy have been disclosed.</p> 
</div>

Sweden issues study on Gripen fighter jet’s satellite launch capability

<div>
 <p>On July 15, 2024, Terran Orbital, a satellite solutions and products manufacturer, declared that it received occupancy certification for its new production facility in Irvine, California. Located on a five-acre plot, the factory, with an area of 94,000 sq ft, is anticipated to triple Terran Orbital's space vehicle assembly, integration, and testing capabilities.</p>
 <p>All of Terran Orbital's space vehicle assembly is set to move to the new site to maximize efficiency and capacity usage. This will free up their existing facilities to concentrate on the manufacture of components and modules. The organization also intends to begin cleanrooms construction by 2025.</p>
</div>

Terran Orbital receives certification for new manufacturing facility to begin production

Clean, congestion-free air travel gets liftoff

Passenger eVTOL Aircraft

ANALYST_QUICK_TAKE

<div>
 <p>Crisalion Mobility, a Spanish aircraft manufacturer, has entered into a partnership with UAE's Air Chateau International.</p>
 <p>As part of the agreement, Air Chateau has pre-ordered 10 Integrity eVTOLs, taking Crisalion's pre-orders to 125. The partners will also collaborate to expand eVTOL air taxi services in UAE's major cities.</p>

</div> <p><b>Analyst QuickTake:<br>
 </b> Crisalion Mobility also recently partnered with iJet Aviation in <a href="https:<br>
//sp-edge.com/updates/30665"> June 2024 </a> and Wilbur Air in <a href="https:<br>
//sp-edge.com/updates/31896"> July 2024 </a> to expand its operations and develop the eVTOL air transportation sector in Malaga and Australia.</p>

All Updates

Formation Bio, Sanofi, and OpenAI partner to accelerate drug development through AI

Robinhood launches joint investment accounts

eToro partners with London Stock Exchange to expand UK stock offerings

StorMagic secures funding from Palatine Growth Credit Fund

Archera raises USD 17 million in Series B funding for product development and recruitment

Alto Neuroscience receives grant of USD 11.7 million to support Phase IIb clinical trials of ALTO-100

Quest Diagnostics and BD partner to develop flow cytometry-based companion diagnostics for cancer and other diseases

USPACE Technology Group Limited unveils commercial optical satellites and related aerospace products

Sweden issues study on Gripen fighter jet’s satellite launch capability

Terran Orbital receives certification for new manufacturing facility to begin production

Crisalion Mobility partners with Air Chateau for pre-order of eVTOL aircraft

AI Drug Discovery

Formation Bio, Sanofi, and OpenAI partner to accelerate drug development through AI

Contact us